FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2015552306> ?p ?o ?g. }

• W2015552306 endingPage "87" @default.
• W2015552306 startingPage "79" @default.
• W2015552306 abstract "Recent advances in molecular biology have led to the development of novel small molecules that target specific viral proteins of the hepatitis C virus (HCV) life cycle. These drugs, collectively termed directly acting antivirals (DAA), include a range of non-structural (NS) 3/NS4A protease, NS5B polymerase and NS5A inhibitors at various stages of clinical development. Some others drugs called ‘non DAA’or indirect inhibitors are not focused on one site of the life cycle target and are still in early pre-clinical and clinical phase I, II and III trials. The rapid replication rate of HCV, along with the low fidelity of its polymerase, results in a generation of mutations throughout the viral genome and sequence variation in the HCV population known as a quasispecies. The efficacy of DAA is limited by the presence of these mutations, resulting in amino acid substitutions within the targeted proteins which affect viral sensitivity to these compounds. Thus, attributable to the high genetic variability of HCV, variants with reduced susceptibility to DAA can occur naturally even before treatment begins, but usually at low levels. Thus it is not surprising that these changes are selected in patients that either breakthrough or do not respond to potent DAA treatment. Six major position mutations in the NS3 HCV Protease (36, 54, 155, 156, 168 and 170), fifteen in the NS5B polymerase (96, 282, 316, 365, 414, 419, 423, 448, 482, 494, 495, 496, 499, 554, 559) and five in the NS5 A region (28, 30, 31, 58 and 93) have now been reported in vitro or in vivo associated with different levels of resistance. The amino acid composition at several of the drug resistance sites can vary between the HCV genotypes/subtypes, resulting in different consensus amino acids leading to a reduction in replicative fitness as well as reduced DAA and non- DAA sensitivity. Information on patterns of resistance to and cross resistance between antiviral agents is increasingly available and may be important for decisions on how to combine drugs to achieve an optimum antiviral effect. This review debates the clinical relevance of resistance to direct and indirect inhibitors taking into account the future potential therapeutic strategies to help patients who do develop resistance to HCV inhibitors. Finally, this chapter treats two points of view: ‘for’ and ‘against’ the question of the importance of resistance." @default.
• W2015552306 created "2016-06-24" @default.
• W2015552306 creator A5027107191 @default.
• W2015552306 creator A5070817587 @default.
• W2015552306 date "2011-12-29" @default.
• W2015552306 modified "2023-09-23" @default.
• W2015552306 title "Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?" @default.
• W2015552306 cites W100710130 @default.
• W2015552306 cites W1497131577 @default.
• W2015552306 cites W1583671795 @default.
• W2015552306 cites W1593744374 @default.
• W2015552306 cites W1969215054 @default.
• W2015552306 cites W1979174109 @default.
• W2015552306 cites W1982433898 @default.
• W2015552306 cites W1983951850 @default.
• W2015552306 cites W1989831705 @default.
• W2015552306 cites W1995565071 @default.
• W2015552306 cites W2007607803 @default.
• W2015552306 cites W2015216410 @default.
• W2015552306 cites W2017412627 @default.
• W2015552306 cites W2019523835 @default.
• W2015552306 cites W2023926449 @default.
• W2015552306 cites W2027545702 @default.
• W2015552306 cites W2029622854 @default.
• W2015552306 cites W2078646756 @default.
• W2015552306 cites W2080237955 @default.
• W2015552306 cites W2088622637 @default.
• W2015552306 cites W2101516953 @default.
• W2015552306 cites W2103185551 @default.
• W2015552306 cites W2110033892 @default.
• W2015552306 cites W2113063960 @default.
• W2015552306 cites W2116705947 @default.
• W2015552306 cites W2117897890 @default.
• W2015552306 cites W2119764771 @default.
• W2015552306 cites W2127685726 @default.
• W2015552306 cites W2129870123 @default.
• W2015552306 cites W2132116288 @default.
• W2015552306 cites W2139311359 @default.
• W2015552306 cites W2141100327 @default.
• W2015552306 cites W2159835094 @default.
• W2015552306 cites W2164301466 @default.
• W2015552306 doi "https://doi.org/10.1111/j.1478-3231.2011.02716.x" @default.
• W2015552306 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22212577" @default.
• W2015552306 hasPublicationYear "2011" @default.
• W2015552306 type Work @default.
• W2015552306 sameAs 2015552306 @default.
• W2015552306 citedByCount "68" @default.
• W2015552306 countsByYear W20155523062012 @default.
• W2015552306 countsByYear W20155523062013 @default.
• W2015552306 countsByYear W20155523062014 @default.
• W2015552306 countsByYear W20155523062015 @default.
• W2015552306 countsByYear W20155523062016 @default.
• W2015552306 countsByYear W20155523062017 @default.
• W2015552306 countsByYear W20155523062018 @default.
• W2015552306 countsByYear W20155523062019 @default.
• W2015552306 countsByYear W20155523062020 @default.
• W2015552306 countsByYear W20155523062021 @default.
• W2015552306 crossrefType "journal-article" @default.
• W2015552306 hasAuthorship W2015552306A5027107191 @default.
• W2015552306 hasAuthorship W2015552306A5070817587 @default.
• W2015552306 hasConcept C104317684 @default.
• W2015552306 hasConcept C132379496 @default.
• W2015552306 hasConcept C14500911 @default.
• W2015552306 hasConcept C159047783 @default.
• W2015552306 hasConcept C181199279 @default.
• W2015552306 hasConcept C2522874641 @default.
• W2015552306 hasConcept C2776408679 @default.
• W2015552306 hasConcept C2776714187 @default.
• W2015552306 hasConcept C2777103181 @default.
• W2015552306 hasConcept C2781426373 @default.
• W2015552306 hasConcept C2781463415 @default.
• W2015552306 hasConcept C2908647359 @default.
• W2015552306 hasConcept C501734568 @default.
• W2015552306 hasConcept C54355233 @default.
• W2015552306 hasConcept C55493867 @default.
• W2015552306 hasConcept C71924100 @default.
• W2015552306 hasConcept C82381507 @default.
• W2015552306 hasConcept C86803240 @default.
• W2015552306 hasConcept C99454951 @default.
• W2015552306 hasConceptScore W2015552306C104317684 @default.
• W2015552306 hasConceptScore W2015552306C132379496 @default.
• W2015552306 hasConceptScore W2015552306C14500911 @default.
• W2015552306 hasConceptScore W2015552306C159047783 @default.
• W2015552306 hasConceptScore W2015552306C181199279 @default.
• W2015552306 hasConceptScore W2015552306C2522874641 @default.
• W2015552306 hasConceptScore W2015552306C2776408679 @default.
• W2015552306 hasConceptScore W2015552306C2776714187 @default.
• W2015552306 hasConceptScore W2015552306C2777103181 @default.
• W2015552306 hasConceptScore W2015552306C2781426373 @default.
• W2015552306 hasConceptScore W2015552306C2781463415 @default.
• W2015552306 hasConceptScore W2015552306C2908647359 @default.
• W2015552306 hasConceptScore W2015552306C501734568 @default.
• W2015552306 hasConceptScore W2015552306C54355233 @default.
• W2015552306 hasConceptScore W2015552306C55493867 @default.
• W2015552306 hasConceptScore W2015552306C71924100 @default.
• W2015552306 hasConceptScore W2015552306C82381507 @default.
• W2015552306 hasConceptScore W2015552306C86803240 @default.
• W2015552306 hasConceptScore W2015552306C99454951 @default.

• next